Precision Business Insights has published a report on the global cancer biomarker testing market, estimating its value at USD 27.6 Billion in 2025 and is expected to expand at a compound annual growth rate (CAGR) of 11.3% over the forecast period 2026-2031. The report explores the market growth and potential opportunities in the market industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period.

View the detailed report description here - https://www.precisionbusinessinsights.com/market-reports/global-cancer-biomarker-testing-market

Market Definition:

In order to identify cancer, forecast the course of the disease, direct the choice of treatment, and track the effectiveness of therapy, laboratory examination of genes, proteins, metabolites, or other molecular indicators present in blood, tissue, or other physiological fluids is known as cancer biomarker testing. Precision/targeted oncology, including companion diagnostics for immunotherapy, targeted therapy, and personalized medicine, is made possible by these biomarkers, which also aid in the identification of particular cancer subtypes.

Drivers:

1) Rising burden of cancer globally.
2) Shift towards precision and personalized medicine.

Key Takeaways:

·         Modern oncology diagnostics and treatment decisions rely heavily on biomarker testing.

·         North America leads the market, with Asia-Pacific showing the fastest growth. Predictive biomarkers dominate demand due to targeted therapy usage.

·         NGS-based tests are the fastest-growing technology segment.

·         Liquid biopsy is quickly gaining traction for recurrence monitoring.

·         Companion diagnostics partnerships between pharma and diagnostics companies are growing.

The global cancer biomarker testing market segmentation:

1) By Type Of Cancer: Cervical cancer, Lung Cancer, Collateral Cancer, Liver Cancer, Prostate Cancer, Breast Cancer, Others.
2) By Application: Drug Discovery and Development, Personalised Medicine, Diagnosis, Others.
3) By End-User: Hospitals, Cancer diagnostic Centres, Research Institutes, Others.

Regional Overview:
The report also examines the current concerns and their Future Effects on the cancer biomarker testing market by the region. The report covers all regions and countries, North America was the largest and Asia was the fastest-growing region in the cancer biomarker testing market. The market has been segmented into numerous primary regions and a detailed evaluation of primary countries.

·         North America (U.S., Canada)

·         Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)

·         Asia-Pacific (China, India, Japan, Australia, Southeast Asia, Rest of Asia Pacific)

·         Latin America (Mexico, Brazil, Argentina, Columbia, Rest of Latin America)

·         Middle East & Africa (GCC, Egypt, Nigeria, South Africa, Rest of Middle East and Africa)

The competitive landscape is dominated by major players like Roche Diagnostics · Thermo Fisher Scientific · Illumina · Agilent Technologies · QIAGEN · Abbott Laboratories · Siemens Healthineers · Bio-Rad Laboratories · Danaher Corporation · Becton Dickinson (BD) · Sysmex Corporation · Foundation Medicine (Roche) · Guardant Health · Exact Sciences · Myriad Genetics · Natera · ArcherDx · F. Hoffmann-La Roche · NeoGenomics Laboratories · BGI Genomics · Adaptive Biotechnologies · ArcherDx · AmoyDx · DiaSorin · Sysmex Inostics · Invitae · Genetron Health · Burning Rock Dx · Sophia Genetics · Roche Tissue Diagnostics · Illumina TruSight · Eurofins Scientific · Luminex (DiaSorin) · Oncoguide (Sysmex) · PathAI · ArcherDx · Veracyte · Cisbio Bioassays · MDxHealth · Genomic Health (Exact Sciences) · Bioneer Corporation · Biocept · Chronix Biomedical · PersonalizeDx · Q2 Solutions · NeoGenomics · ArcherDx

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

Contact:
Mr. Satya
Precision Business Insights | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 852781747